ACS (Oxford Handbook of Clinical Pharmacy 2e) Flashcards Preview

Advanced Pharmacy Practice > ACS (Oxford Handbook of Clinical Pharmacy 2e) > Flashcards

Flashcards in ACS (Oxford Handbook of Clinical Pharmacy 2e) Deck (23)
Loading flashcards...
1
Q

The prehospital management of a STEMI consists of [4]

A
  1. GTN spray 400micrograms s/l, repeat after 5 min (max 2 doses) if available to take.
  2. GTM tablet 500micrograms s/l, maximum 1500, if availble.
  3. Supplemental oxygen.
  4. If Dr present: Morphine 2.5-5mg IV repeat as necessary. (think about laxatives, anti-emetics later on).
2
Q

What does the immediate and early hospital management of STEMI consist of? [4]

A
  1. ECG: if STEMI diagosed:
  2. Aspirin 300mg chewed or dissolved before swallowing plus 02 therapy.
    - NB: patients with severe obstructive airway disease could underventilate with 02 therapy and retain C02 becoming drowsy.
  3. For chest pain: GTN 500micrograms s/l, repeat ater 5 mins if pain persists and SBP >95mmhg.
  4. For persisting chest pain: Morphine 2.5-5mg IV PRN plus reperfusion therapy.
3
Q

What is PCI?

A

This is the reperfusion therapy of choice.

Adjuvant therapy for PCI includes aspirin/clopidogrel and heparin. Some patients need a glycoprotein IIb/IIIa inhibitor.

4
Q

What does adjuvant therapy for PCI consist of? [3]

A

Adjuvant therapy for PCI includes aspirin/clopidogrel (1) and heparin (2). Some patients need a glycoprotein IIb/IIIa inhibitor (3).

5
Q

In the management of STEMI, when is fibrinolytic therapy indicated? (2)

A

Prolonged ischaemic chest pain that has begun within the previous 12 hours (1) in the presence of ST segment elevation (2) or left bundle branch block.

6
Q

Patients who cannot have fibrinolytic therapy for STEMI should have what?

A

PCI

7
Q

For STEMI patients who can have fibrinolytic agents, what can be used?

A
  1. Alteplase
  2. Reteplase
  3. Streptokinase
  4. Tenecteplase

The plasminogen activators: alteplase, reteplase and tenecteplase are superior to streptokinase but considerably more expensive.

8
Q

Why is there a risk of allergic reactions in patients having a second treatment of streptokinase within 1 year of the previous treatment?

A

Antibodies are generated for streptokinase - it should not be used again beyond 4 days of first administration.

9
Q

How can we reverse heparin?

A

Protamine. Dosage depends on level of anticoagulation.

10
Q

The routine management of patients with acute MI with magnesium

A

NOPE

11
Q

What does subsequent management of patients with STEMI consist of? [5]

A
  1. Coronary angiography normally to investigate and then initiation of aspirin 75-300mg daily or if intolerant clopidogrel 75mg oral daily.
  2. B-Blocker therapy: Atenolol 25-100mg oral daily etc. titrate to maximum tolerated dose, do not allow SBP <95mmHg or heart rate <55.
  3. ACEi therapy or ARB if ACEi intolerance
  4. Statin therapy: atorvastatin.
  5. CCB: this should be reserved for those who have post-MI angina and CIs to BB.
12
Q

When would CCB be used post STEMI?

A

When cannot tolerate BB or post-MI angina occurs.

13
Q

What does intitial therapy for high-risk unstable angina and NSTEMI patients consist of? [6]

A
  1. Hospitalisation
  2. ECG
  3. Platelet inhibition
  4. Antithrombin therapy
  5. BB therapy
  6. Potentially glycoprotein IIa/IIIb inhibitors and revascularisation
14
Q

For UA/NSTEMI patients who are nable to use BB, what can be used?

A

Non-dihydropyridine CCB
Dilitiazem 30-120mg oral, tds.
Diltiazem controlled release 180-360mg oral, daily.
Verapamil etc.

15
Q

For patients in whom UA has not be controlled with a BB alone what can be added?

A

A NON-RL CCB:
NOT DILT or VER
Nifedipine or amlodipine

16
Q

Patients who have undergone revascularisation procedures including a coronary stent must be on what drugs and for how long?

A

Aspirin AND clopidogrel for at least 1 month.

If using drug-eluting stent: at least 3 months.

17
Q

In the management of NSTEMI/UA what does platelet inhibition take the form of?

A

Aspirin 75-300mg oral, daily and clopidogrel 75mg oral, daily with an initial stat dose of 300mg (sometimes 600???)

18
Q

In the management of NSTEMI/UA what does antithrombin therapy take the form of?

A

UFH or LMWH in addition to the Aspirin that the patient will be initiated onto.

UFH/LMWH should be used for at least 3 das and possibly longer.

LMWH advantages: subcut, no constant monitoring.
Disadvantages: cannot be easily reversed.

For patients on UFH, the APTT should be checked initially every 6h, with a target range of 60-80s and shold be checked daily after therapy has been stabilised.

19
Q

What BB should we use in people with UA/NSTEMI

A

Atenolol or metoprolol are recommened (according to this book - might be out of date)

20
Q

When would the use of GP IIb/IIIa inhibitors occur in UA/NSTEMI management?

A
  1. PAtients might be treated in the coronary care unit (with tirofiban only) for a number of hours before undergoing investigation and PCI, if needed.
  2. PAtients might be treated with abiciximab at the time of procedure.

They are recommended for people who are at high risk and have abnormal ECG or a positive tropinin test.

21
Q

What is tirofaban? [3]

A

Non-peptide antagonist of GP IIb/IIIc receptors.
Approved for use in combination with heparin for patients with UA who are being treated medically and for those undergoing PCI.
When administered IV, more than 90% of platelet aggregation is inhibited.

22
Q

What is Abciximab? (3)

A
  1. Chimeric human-murine monoclonal antibody
  2. Elective, urgent or emergent PCI
  3. Binds to receptor with high affinity and reduces platelet aggregation 80%.
23
Q

What is Eptifibatide?

A
  1. Antagonist of the platelet glycoprotein IIb/IIIc eceptor which reversibly prevents von Willebrand factor, fibrinogen and other adhesion ligands from binding to the receptor.
  2. Used for preventon of early MI in patients with unstable angina or NSTEMI with last episode of chest pain within 24h.